Company Overview and News


Add CYTX
to your dashboard

Headline News

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Third Quarter 2017 Earnings Results Call. [Operator Instructions]. (25-0)

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics’ Second Quarter 2017 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation. [Operator Instructions] (0-1)

The Big Deal About Stem Cell Therapies and Regenerative Medicine

2017-07-28 prnewswire
Stem cell therapies are a key component of the regenerative medicine field that promises to be a revolutionary approach to treating many degenerative conditions by repairing damaged tissue and harnessing the body's ability to heal itself. Biotech companies in focus include: Endonovo Therapeutics, Inc. (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), Cytori Therapeutics, Inc. (0-1)

Biotech Forum Daily Digest: Dynavax Technologies' Moment Of Truth Arrives

2017-07-24 seekingalpha
The main biotech indices continue to push higher last week as second quarter earnings from industry stalwarts start to filter in. (0-2)

San Diego's Cytori Plunges Scleroderma Med Flunks Phase III Study

2017-07-24 biospace
SAN DIEGO, July 24, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced top-line, preliminary data from its pivotal STAR trial of HabeoTM Cell Therapy in patients with scleroderma. While the primary endpoint, Cochin Hand Function Score (CHFS), did not reach statistical significance at 24 or 48 weeks, the trial data reported clinically meaningful improvements in the primary and secondary endpoints of both hand function and scleroderma-associated functional disability, for Habeo treated patients compared to placebo, in a subgroup of patients with diffuse cutaneous scleroderma. (0-3)

Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock?

2017-07-07 zacks
Investors in Cytori Therapeutics, Inc. (CYTX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the December 15th, 2017, $2 Call had some of the highest implied volatility of all equity options today. (0-1)

Long Term Safety Data Published On Cytori Technology For Breast Reconstruction After Oncologic Surgery & Radiation Therapy

2017-06-08 devicespace
SAN DIEGO, June 08, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced the publication of long-term follow-up data reporting patient satisfaction and surveillance for cancer recurrences following use of Cytori Cell Therapy™ for breast reconstruction following partial mastectomy and radiation for breast cancer treatment. (0-1)

Cytori To Introduce Next-Generation Celution Technology

2017-06-01 devicespace
SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced plans to introduce its next-generation Celution® technology.  The technology is available for pre-orders effective June 1st, 2017 with first product shipments anticipated to begin in Q3.

BRIEF-Cytori Therapeutics completes follow up monitoring visits in FDA approved late-stage STAR trial

2017-05-23 reuters
* Cytori Therapeutics Inc - now completed all 48 week follow up monitoring visits in its U.S. FDA approved phase III star trial Source text for Eikon: Further company coverage:

Regenerative Medicine Market to Grow Over $53.7 Billion by 2021 With 23.3% CAGR Says a Report at ReportsnReports.com

2017-05-17 prnewswire
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.

Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2017 Results - Earnings Call Transcript

2017-05-12 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics’ First Quarter 2017 Earnings Results Call.

Linde CEO sees new company after Praxair merger based in Ireland

2017-05-10 reuters
MUNICH May 10 The new company formed from the planned $70 billion merger of Linde and Praxair will likely be based in Ireland with a tax domicile in Britain, its chief executive told shareholders on Wednesday.

BRIEF-Nuance and Lexmark form strategic partnership

2017-05-10 reuters
* Cytori Therapeutics Inc - one year follow up data of adrcs (cytori cell therapy) treatment in post prostatectomy erectile dysfunction

BRIEF-Vulcan reports Q1 earnings per share $0.32 from continuing operations

2017-05-10 reuters
* Vulcan Materials Co qtrly total revenues increased $33 million, or 4 percent, to $787 million

CUSIP: 23283K204